publication date: Aug. 2, 2019
NCI Trials
NCI Trials for August
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – AMC-105
A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma
AIDS Malignancy Consortium
Tan, Carlyn Rose
(215) 214-3119
Phase II – 10240
Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Ohio State University Comprehensive Cancer Center LAO
Konda, Bhavana
(614) 293-8629
Phase II – ABTC-1802
A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Adult Brain Tumor Consortium
Grossman, Stuart Alan
(410) 955-8837
Phase II/III – NRG-HN005
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
NRG Oncology
Yom, Sue Sun
(415) 353-7175
Phase III – A071801
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
Alliance for Clinical Trials in Oncology
Brown, Paul D.
(713) 563-2415
Phase III – AALL1732
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted … Continue reading NCI Trials for August 2019To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
